| Nome |
# |
|
The hemostatic system. 1st Part, file e2f56ed8-fa71-3eaf-e053-3a05fe0a5d97
|
706
|
|
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study, file e2f56ed4-cf47-3eaf-e053-3a05fe0a5d97
|
371
|
|
Heterogeneity of Antiphospholipid Syndrome (APS) as Characterized by Brain Perfusion Techniques. Towards New Ways of Syndrome Characterization, file e2f56ed8-b3d6-3eaf-e053-3a05fe0a5d97
|
362
|
|
High frequency of inadequate test requests for antiphospholipid antibodies in daily clinical practice, file e2f56ed3-9d39-3eaf-e053-3a05fe0a5d97
|
337
|
|
Optimizing tailored DIEP flap insetting in unilateral immediate free autologous breast reconstruction, file e2f56ed9-21bb-3eaf-e053-3a05fe0a5d97
|
270
|
|
Vaccine-induced severe thrombotic thrombocytopenia following COVID-19 vaccination: A report of an autoptic case and review of the literature, file e2f56ed9-f034-3eaf-e053-3a05fe0a5d97
|
169
|
|
Risk of reoperation in bioprosthetic valve patients with indication for longterm anticoagulation. Results from the observational retrospective multicentre PLECTRUM study, file e2f56ed7-a3af-3eaf-e053-3a05fe0a5d97
|
163
|
|
Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience, file e2f56ed9-5c39-3eaf-e053-3a05fe0a5d97
|
163
|
|
Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review, file e2f56ed9-7f13-3eaf-e053-3a05fe0a5d97
|
162
|
|
Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA(2)DS(2)VASc 1 or 2): a treatment dilemma, file e2f56ed7-4edc-3eaf-e053-3a05fe0a5d97
|
139
|
|
Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago, file e2f56ed7-3395-3eaf-e053-3a05fe0a5d97
|
131
|
|
The Italian START-Register on anticoagulation with focus on atrial fibrillation, file e2f56ed7-663a-3eaf-e053-3a05fe0a5d97
|
102
|
|
A “Catastrophic” Heparin-Induced Thrombocytopenia, file e2f56ed9-2ba9-3eaf-e053-3a05fe0a5d97
|
78
|
|
A guide to oral anticoagulation, file e2f56ed7-d339-3eaf-e053-3a05fe0a5d97
|
42
|
|
Fondaparinux: Should It Be Studied in Patients with COVID-19 Disease?, file e2f56ed9-4e6e-3eaf-e053-3a05fe0a5d97
|
41
|
|
Hyperhomocysteinemia: could the post-methionine oral loading test sometimes be avoided?, file e2f56ed3-b44c-3eaf-e053-3a05fe0a5d97
|
28
|
|
The criteria of the Italian Federation of Thrombosis Centres on DOACs: a ‘‘real world’’ application in nonvalvular atrial fibrillation patients already on Vitamin K Antagonist, file e2f56ed3-8ab3-3eaf-e053-3a05fe0a5d97
|
24
|
|
Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation, file e2f56ed3-c200-3eaf-e053-3a05fe0a5d97
|
20
|
|
The venous thromboembolic risk and the clot wave analysis: a useful relationship?, file e2f56ed7-1565-3eaf-e053-3a05fe0a5d97
|
12
|
|
Olanzapine-associated portal and superior mesenteric vein thrombosis, file e2f56ed8-c550-3eaf-e053-3a05fe0a5d97
|
11
|
|
Clot characterization by multidisciplinary approach: biochemical and imaging parameters in a hypocoagulative setting. A pilot study, file e2f56ed9-bb71-3eaf-e053-3a05fe0a5d97
|
9
|
|
Center-related determinants of VKA anticoagulation quality: A prospective, multicenter evaluation, file e2f56eda-6c2f-3eaf-e053-3a05fe0a5d97
|
9
|
|
Point-of-care testing INR: an overview, file e2f56ed6-6988-3eaf-e053-3a05fe0a5d97
|
8
|
|
Fatal Cytopenia Induced by Low-Dose Methotrexate in Elderly With Rheumatoid Arthritis. Identification of Risk Factors, file e2f56ed6-48db-3eaf-e053-3a05fe0a5d97
|
7
|
|
Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules in patients on oral anticoagulants, file e2f56ed6-73b2-3eaf-e053-3a05fe0a5d97
|
7
|
|
A ‘‘two-step’’ educational approach for patients taking oral anticoagulants does not improve therapy control, file e2f56ed3-8235-3eaf-e053-3a05fe0a5d97
|
6
|
|
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a reply to a rebuttal, file e2f56ed3-8db5-3eaf-e053-3a05fe0a5d97
|
6
|
|
Prophylaxis of peripartum haemorrhage using recombinant factor VIIa (rfVIIa) in pregnant women with congenital factor VII deficiency: A case report and literature review, file e2f56ed8-2277-3eaf-e053-3a05fe0a5d97
|
6
|
|
Vitamin K antagonists (coumarins), drugs used in the prevention and treatment of cardioembolism, deep vein thrombosis, and pulmonary embolism, file e2f56ed6-5918-3eaf-e053-3a05fe0a5d97
|
5
|
|
Points of Care Testing International Normalized Ratio: Are They Useful for Monitoring Vitamin K Antagonists in a Thrombosis Center?, file e2f56ed7-8a95-3eaf-e053-3a05fe0a5d97
|
5
|
|
A retrospective cohort study of patients with pulmonary embolism: The impact of comorbidities on patient's outcome, file e2f56ed7-d74a-3eaf-e053-3a05fe0a5d97
|
5
|
|
Are prothrombin time and clot waveform analysis useful in detecting a bleeding risk in liver cirrhosis?, file e2f56ed8-4eef-3eaf-e053-3a05fe0a5d97
|
5
|
|
Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study, file e2f56ed8-6130-3eaf-e053-3a05fe0a5d97
|
5
|
|
Ultrastructural findings of lung injury due to Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT) following COVID-19 vaccination: a scanning electron microscopic study, file e2f56eda-8794-3eaf-e053-3a05fe0a5d97
|
5
|
|
The predictive ability of bleeding risk stratification models in very old patients on vitaminK antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study, file e2f56ed3-8db4-3eaf-e053-3a05fe0a5d97
|
4
|
|
Point-of-care (POCT) prothrombin time monitors: is a periodical control of their performance useful?, file e2f56ed3-9da2-3eaf-e053-3a05fe0a5d97
|
4
|
|
Direct inhibitors of thrombin and factor Xa: the importance of laboratory skills, file e2f56ed3-a733-3eaf-e053-3a05fe0a5d97
|
4
|
|
Antiphospholipid syndrome patients: The performance of Coagucheck XS in the monitoring of Vitamin K-Antagonists, file e2f56ed3-a82d-3eaf-e053-3a05fe0a5d97
|
4
|
|
Telemedicine can improve the quality of oral anticoagulation using portable devices and self-testing at home, file e2f56ed3-abbe-3eaf-e053-3a05fe0a5d97
|
4
|
|
Superior sagittal sinus thrombosis after lumbar puncture in a patient with T-cell lymphoblastic lymphoma: role of the prothrombin G20210A mutation and 4G/4G genotype, file e2f56ed3-b3a1-3eaf-e053-3a05fe0a5d97
|
4
|
|
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome, file e2f56ed3-b4e3-3eaf-e053-3a05fe0a5d97
|
4
|
|
Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment., file e2f56ed6-49c9-3eaf-e053-3a05fe0a5d97
|
4
|
|
Clot wave analysis and thromboembolic score in liver cirrhosis: two opposing phenomena, file e2f56ed6-c40b-3eaf-e053-3a05fe0a5d97
|
4
|
|
Direct oral anticoagulants: what can we learn?, file e2f56ed7-1b0e-3eaf-e053-3a05fe0a5d97
|
4
|
|
Comparison of prothrombin time INR and clot waveform analysis performed with 129-mmol/L and 105-mmol/L citrate tubes, file e2f56ed7-6f48-3eaf-e053-3a05fe0a5d97
|
4
|
|
A Sardinian Family with Factor XI Deficiency, file e2f56ed8-a54d-3eaf-e053-3a05fe0a5d97
|
4
|
|
Heparins and 2019-nCoV infection: a narrative review, file e2f56ed9-d54b-3eaf-e053-3a05fe0a5d97
|
4
|
|
Scanning electron microscopy of lung disease due to COVID-19 – a case report and a review of the literature, file e2f56eda-75d3-3eaf-e053-3a05fe0a5d97
|
4
|
|
Chronic intravascular coagulation in liver cirrhosis predicts a high hemorrhagic risk, file e2f56eda-9016-3eaf-e053-3a05fe0a5d97
|
4
|
|
Over-anticoagulation by vitamin K antagonists and gender differences, file 03737d25-3e09-4c54-b30b-dfefc6eb5d1e
|
3
|
|
Rheumatoid arthritis and thrombosis, file e2f56ed3-b2d9-3eaf-e053-3a05fe0a5d97
|
3
|
|
Thyroid disorders and hypocoagulability, file e2f56ed3-d81d-3eaf-e053-3a05fe0a5d97
|
3
|
|
Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA), file e2f56ed4-d69f-3eaf-e053-3a05fe0a5d97
|
3
|
|
Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? No, file e2f56ed7-c2d3-3eaf-e053-3a05fe0a5d97
|
3
|
|
Management of Patients Taking Oral Anticoagulants Who Need Urgent Surgery for Hip Fracture, file e2f56ed8-13f6-3eaf-e053-3a05fe0a5d97
|
3
|
|
Prophylaxis of peripartum haemorrhage using recombinant factor VIIa (rfVIIa) in pregnant women with congenital factor VII deficiency: A case report and literature review, file e2f56ed8-9aa2-3eaf-e053-3a05fe0a5d97
|
3
|
|
Bleeding diathesis and gastro-duodenal ulcers in inherited cytosolic phospholipase-A2 alpha deficiency, file e2f56ed8-af34-3eaf-e053-3a05fe0a5d97
|
3
|
|
Vaping effects on asthma: results from a web survey and clinical investigation, file e2f56ed8-f4b9-3eaf-e053-3a05fe0a5d97
|
3
|
|
Infectious agents including COVID-19 and the involvement of blood coagulation and fibrinolysis. A narrative review, file e2f56ed9-d94d-3eaf-e053-3a05fe0a5d97
|
3
|
|
Chronic spontaneous urticaria: a low-grade disseminated intravascular coagulation only partially reversed by Omalizumab, file 3d3798f9-5949-45fa-a4fc-392e9a820f7c
|
2
|
|
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results, file e2f56ed3-8db6-3eaf-e053-3a05fe0a5d97
|
2
|
|
Management of special conditions in patients on vitamin K antagonists, file e2f56ed3-8db7-3eaf-e053-3a05fe0a5d97
|
2
|
|
Special indications for vitamin K antagonists: a review, file e2f56ed3-948d-3eaf-e053-3a05fe0a5d97
|
2
|
|
Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA), file e2f56ed3-a473-3eaf-e053-3a05fe0a5d97
|
2
|
|
null, file e2f56ed3-a4e5-3eaf-e053-3a05fe0a5d97
|
2
|
|
A routine silica-based activated partial thromboplastin time (Hemosil aPTT-SP (TM)) mostly excludes the presence of lupus anticoagulant, file e2f56ed3-af27-3eaf-e053-3a05fe0a5d97
|
2
|
|
Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2(V617F) mutation, file e2f56ed3-b39c-3eaf-e053-3a05fe0a5d97
|
2
|
|
Acquired factor VIII inhibitor and subsequent development of non-Hodgkin's lymphoma: a case report and review of the literature, file e2f56ed5-8bbc-3eaf-e053-3a05fe0a5d97
|
2
|
|
Pulmonary Thrombosis: A Clinical Pathological Entity Distinct from Pulmonary Embolism?, file e2f56ed8-bc4a-3eaf-e053-3a05fe0a5d97
|
2
|
|
Pulmonary thrombosis in 2019-nCoV pneumonia?, file e2f56ed9-23b2-3eaf-e053-3a05fe0a5d97
|
2
|
|
null, file e2f56ed3-9a17-3eaf-e053-3a05fe0a5d97
|
1
|
|
null, file e2f56ed3-9f43-3eaf-e053-3a05fe0a5d97
|
1
|
|
null, file e2f56ed3-b146-3eaf-e053-3a05fe0a5d97
|
1
|
|
null, file e2f56ed3-ba56-3eaf-e053-3a05fe0a5d97
|
1
|
|
null, file e2f56ed3-bf87-3eaf-e053-3a05fe0a5d97
|
1
|
|
Hemarthrosis as acute presentation of acquired hemophilia in a patient with systemic lupus erythematosus: successful treatment and long-lasting remission, file e2f56ed3-bff2-3eaf-e053-3a05fe0a5d97
|
1
|
|
Allele 4G of gene PAI-I associated with prothrombin mutation G20210A increases the risk for venous thrombosis, file e2f56ed3-c017-3eaf-e053-3a05fe0a5d97
|
1
|
|
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study, file e2f56ed7-cdba-3eaf-e053-3a05fe0a5d97
|
1
|
|
Underuse of anticoagulant therapy in hospitalized older patients: comment on the article of Wojszel et al, file e2f56ed8-b513-3eaf-e053-3a05fe0a5d97
|
1
|
|
Thrombosis centres and AVKs monitoring in COVID-19 pandemic, file e2f56ed9-8e61-3eaf-e053-3a05fe0a5d97
|
1
|
|
Empathy and the Educational Approach to Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants, file e2f56ed9-b9df-3eaf-e053-3a05fe0a5d97
|
1
|
|
The Repeatable Battery for the Assessment of Neuropsychological Status as a screening strategy for HIV-Associated Neurocognitive Disorders, file e2f56ed9-ff7e-3eaf-e053-3a05fe0a5d97
|
1
|
|
Clinical history and gastrointestinal bleeding in patients taking oral anticoagulants, file e2f56eda-0e27-3eaf-e053-3a05fe0a5d97
|
1
|
| Totale |
3544 |